EMA rejects Alzheimer’s drug Leqembi over safety concerns

The European Medicines Agency has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen, due to concerns over rare brain swelling side effects. The committee's decision follows the drug's approval in the US, where it is projected to generate $154 million in revenue this year. Approximately 50 million people globally are affected by Alzheimer’s, with 6.9 million in the EU.